CG Oncology (CGON) Non-Current Assets (2023 - 2026)
CG Oncology's (CGON) quarterly Non-Current Assets came in at $33.1 million in Q1 2026, up 22.71% YoY from $27.0 million in Q1 2025, and up 3.12% on a QoQ basis from $32.1 million in Q4 2025.
CG Oncology (CGON) Non-Current Assets (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Non-Current Assets data on file, last reported at $33.1 million in Q1 2026.
- Quarterly Non-Current Assets rose 22.71% year-over-year to $33.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $127.8 million (up 349.39% YoY) and the FY2025 annual result came in at $32.1 million, up 5371.38% from the prior year.
- Non-Current Assets advanced to $33.1 million in Q1 2026, from $32.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $34.1 million in Q3 2025 to a low of $391000.0 in Q3 2024.
- A 4-year average of $16.2 million and a median of $16.1 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets plunged 88.66% — and 2025, when it jumped 8627.11%.
- Tracing CGON's Non-Current Assets over 4 years: stood at $5.2 million in 2023, then sank by 88.66% to $587000.0 in 2024, then soared by 5371.38% to $32.1 million in 2025, then climbed by 3.12% to $33.1 million in 2026.
- The last three Non-Current Assets figures came in at $33.1 million (Q1 2026), $32.1 million (Q4 2025), and $34.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 36.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.01 Mn |
| Mar 31, 2026 | 33.12 Mn |
| Dec 31, 2025 | 32.12 Mn |
| Sep 30, 2025 | 34.12 Mn |
| Jun 30, 2025 | 28.42 Mn |
| Mar 31, 2025 | 26.99 Mn |
| Dec 31, 2024 | 587,000.00 |
| Sep 30, 2024 | 391,000.00 |
| Jun 30, 2024 | 466,000.00 |
| Mar 31, 2024 | 498,000.00 |
| Dec 31, 2023 | 5.18 Mn |